Patient leaflet - Optruma
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet
-
1. What Optruma is and what it is used for
-
2. What you need to know before you take Optruma
-
3. How to take Optruma
-
4. Possible side effects
-
5. How to store Optruma
-
6. Contents of the pack and other information
1. What Optruma is and what it is used for
Optruma contains the active substance raloxifene hydrochloride.
Optruma is used to treat and prevent osteoporosis in postmenopausal women. Optruma reduces the risk of vertebral fractures in women with postmenopausal osteoporosis. A reduction in the risk of hip fractures has not been shown.
How Optruma works
Optruma belongs to a group of non-hormonal medicines called Selective Oestrogen Receptor Modulators (SERMs). When a woman reaches the menopause, the level of the female sex hormone oestrogen goes down. Optruma mimics some of the helpful effects of oestrogen after the menopause.
Osteoporosis is a disease that causes your bones to become thin and fragile – this disease is especially common in women after the menopause. Although it may have no symptoms at first, osteoporosis makes you more likely to break bones, especially in your spine, hips and wrists and may cause back pain, loss of height and a curved back.
2. What you need to know before you take Optruma
Do not take Optruma:
- If you are being treated or have been treated for blood clots in the legs (deep vein thrombosis), in the lungs (pulmonary embolism) or in the eyes (retinal vein thrombosis).
- If you are allergic (hypersensitive) to raloxifene or any of the other ingredients of this medicine (listed in section 6).
- If there is still a possibility that you can get pregnant, Optruma could harm your unborn child.
- If you have liver disease (examples of liver disease include cirrhosis, mild hepatic impairment
or cholestatic jaundice).
- If you have severe kidney problems.
- If you have any unexplained vaginal bleeding. This must be investigated by your doctor.
- If you have active uterine cancer, as there is insufficient experience of Optruma use in women with this disease.
Warnings and precautions
Talk to your doctor or pharmacist before you take Optruma.
- If you are immobilised for some time such as being wheel-chair bound, needing to be admitted to a hospital or having to stay in bed while recovering from an operation or an unexpected illness as these may increase your risk of blood clots (deep vein thrombosis, pulmonary embolism or retinal vein thrombosis).
- If you have had a cerebrovascular accident (e.g. stroke), or if your doctor has told you that you are at high risk of having one.
- If you have liver disease
- If you are suffering from breast cancer, as there is insufficient experience of Optruma use in women with this disease.
- If you are receiving oral oestrogen therapy.
It is unlikely that Optruma will cause vaginal bleeding. So any vaginal bleeding while you take Optruma is unexpected. You should have this investigated by your doctor.
Optruma does not treat postmenopausal symptoms, such as hot flushes.
Optruma lowers total cholesterol and LDL („bad“) cholesterol. In general, it does not change triglycerides or HDL („good“) cholesterol. However, if you have taken oestrogen in the past and had extreme elevations in triglycerides, you should talk to your doctor before taking Optruma.
Optruma contains lactose
If you have been told by your doctor that you have an intolerance to lactose, a type of sugar, contact your doctor before taking this medicinal product.
Other medicines and Optruma
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
If you are taking digitalis medicines for your heart or anticoagulants like warfarin to thin your blood, your doctor may need to adjust your dose of these medicines.
Tell your doctor if you are taking cholestyramine which is mainly used as lipid-lowering medicine, because Optruma may not work as well.
Pregnancy and breast-feeding
Optruma is for use only by postmenopausal women and must not be taken by women who could still have a baby. Optruma could harm your unborn child.
Do not take Optruma if you are breast-feeding as it might be excreted in mother's milk.
Driving and using machines
Optruma has no or negligible effects on driving or using machines.
3. How to take Optruma
Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.
The dose is one tablet a day. It does not matter what time of day you take your tablet but taking the tablet at the same time each day will help you remember to take it. You may take it with or without food.
The tablets are for oral use.
Swallow the tablet whole. If you wish you may take a glass of water with it. Do not break or crush the tablet before taking it. A broken or crushed tablet may taste bad and there is a possibility that you will receive an incorrect dose.
Your doctor will tell you how long you should continue to take Optruma. The doctor may also advise you to take calcium and vitamin D supplements.
If you take more Optruma than you should
Tell your doctor or pharmacist. If you take more Optruma than you should you could have leg cramps and dizziness.
If you forget to take Optruma
Take a tablet as soon as you remember and then continue as before. Do not take a double dose to make up for a forgotten tablet dose.
If you stop taking Optruma
You should talk to your doctor first.
It is important that you continue taking Optruma for as long as your doctor prescribes the medicine, Optruma can treat or prevent your osteoporosis only if you continue to take the tablets.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects although not everybody gets them. The majority of side effects seen with Optruma have been mild.
The most common side effects (affects more than 1 user in 10) are:
- Hot flushes (vasodilatation)
- Flu syndrome
- Gastrointestinal symptoms such as nausea, vomiting, abdominal pain and stomach upset
- Increased blood pressure
Common side effects (affects 1 to 10 users in 100) are:
- Headache including migraine
- Leg cramps
- Swelling of hands, feet and legs (peripheral oedema)
- Gallstones
- Rash
- Mild breast symptoms such as pain, enlargement and tenderness
Uncommon side effects (affects 1 to 10 users in 1000) are:
- Increased risk of blood clots in the legs (deep vein thrombosis)
- Increased risk of blood clots in the lungs (pulmonary embolism)
- Increased risk of blood clots in the eyes (retinal vein thrombosis)
- Skin around the vein is red and painful (superficial vein thrombophlebitis)
- Blood clot in an artery (for example stroke, including an increased risk of dying from stroke)
- Decrease in the number of the platelets in the blood
In rare cases, blood levels of liver enzymes may increase during treatment with Optruma.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Optruma
Keep this medicine out of the sight and reach of children.
Do not use after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.
Store in the original package. Do not freeze.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Optruma contains
-
– The active substance is raloxifene hydrochloride. Each tablet contains 60 mg of raloxifene hydrochloride, which is equivalent to 56 mg raloxifene.
-
– The other ingredients are:
What Optruma looks like and contents of the pack
Optruma are white, oval, film coated tablets which are marked with the number 4165. They are packed in blisters or in plastic bottles. The blister boxes contain 14, 28 or 84 tablets. The bottles contain 100 tablets. Not all pack sizes may be marketed.
Marketing Authorisation Holder
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands
Manufacturer
Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas (Madrid), Spain.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
| België/Belgique/Belgien | Lietuva |
| Eli Lilly Benelux S.A./N.V. | Eli Lilly Lietuva |
| Tél/Tel: + 32-(0)2 548 84 84 | Tel. +370 (5) 2649600 |
| Etnrapua | Luxembourg/Luxemburg |
| Tn „Enu ^unu HegepnaHg“ E.B. – E^nrapua | Eli Lilly Benelux S.A./N.V. |
| men. + 359 2 491 41 40 | Tél/Tel: + 32-(0)2 548 84 84 |
| Česká republika | Magyarország |
| ELI LILLY ČR, s.r.o. | Lilly Hungária Kft. |
| Tel: + 420 234 664 111 | Tel: + 36 1 328 5100 |
| Danmark | Malta |
| Eli Lilly Danmark A/S | Charles de Giorgio Ltd. |
| Tlf: +45 45 26 60 00 | Tel: + 356 25600 500 |
| Deutschland | Nederland |
| Daiichi Sankyo Deutschland GmbH | Eli Lilly Nederland B.V. |
| Tel. +49-(0) 89 78080 | Tel: + 31-(0) 30 60 25 800 |
| Eesti | Norge |
| Eli Lilly Nederland B.V. | Eli Lilly Norge A.S. |
| Tel: +372 6 817 280 | Tlf: + 47 22 88 18 00 |
| EXÀàôa | Österreich |
| OAPMAZEPB-AIAAY A.E.B.E. | Eli Lilly Ges.m.b.H. |
| Tql: +30 210 629 4600 | Tel: + 43-(0) 1 711 780 |
| España | Polska |
| Lilly S.A. | Eli Lilly Polska Sp. z o.o. |
| Tel: +34–91–663 50 00 | Tel: +48 22 440 33 00 |
| France | Portugal |
| Pierre Fabre Médicament | Laboratórios Vitória S.A. |
| Tél: + 33-(0) 1 49 10 80 00 | Tel: + 351– 21 4758300 |
| Hrvatska | România |
| Eli Lilly Hrvatska d.o.o. | Eli Lilly România S.R.L. |
| Tel: +385 1 2350 999 | Tel: + 40 21 4023000 |
| Ireland | Slovenija |
| Eli Lilly and Company (Ireland) Limited | Eli Lilly farmacevtska družba, d.o.o. |
| Tel: + 353-(0) 1 661 4377 | Tel: +386 (0)1 580 00 10 |
| Ísland | Slovenská republika |
| Icepharma hf. | Eli Lilly Slovakia s.r.o. |
| Sími + 354 540 8000 | Tel: + 421 220 663 111 |
| Italia | Suomi/Finland |
| A. Menarini | Oy Eli Lilly Finland Ab |
| Industrie Farmaceutiche Riunite s.r.l. | Puh/Tel: + 358-(0) 9 85 45 250 |
| Tel: +39–055 56801 | |
| Kùnpoç | Sverige |
| Phadisco Ltd | Eli Lilly Sweden AB |
| Tql: +357 22 715000 | Tel: + 46-(0) 8 7378800 |
| Latvija | United Kingdom (Northern Ireland) |
| Eli Lilly (Suisse) S.A Pärstävnieciba Latvijä | Eli Lilly and Company (Ireland) Limited |
| Tel: +371 67364000 | Tel: + 353-(0) 1 661 4377 |
This leaflet was last revised in month YYYY.
Detailed information on this medicine is available on the European Medicines Agency (EMA) web site:
27